Investing Profile

Joël Jean-Mairet

ysioscapital.com/management-t...

Your Intro Paths to Joël Jean-Mairet

Signal uses Gmail to reveal intro paths. Email content is never read.

Find Joël Jean-Mairet on

Current Investing Position

Ysios Capital General Partner

Investment Range

$1M - $7.5M

Sweet Spot

$1M

Investments On Record

Current Fund Size

€126.4M

Joël Jean-Mairet is on these Sector & Stage Rankings

BioTech (Seed)Health IT (Seed)

Joël Jean-Mairet's Investments On Record (10)

Company	StageDateRound Size	Total Raised
ADCendo	Series CApr 2026$75M Series BNov 2024$140M Series AApr 2023$34M Series AApr 2021$62M	$320M
Co-investors: Ohad Hammer (Pontifax Venture Capital), Iyona Rajkomar (Pontifax Venture Capital), Reza Halse (RA Capital), Marten Steen (HealthCap), Rajul Jain (Vida Ventures)
Splice Bio	Series BJun 2025$140M Series AFeb 2022$57M Series UnknownSep 2020	$190M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Sylvain Sachot (Asabys Partners), Beat Steffen (Novartis Venture Fund), Daniela Begolo (EQT Life Sciences), Laia Crespo (Sanofi Ventures), Carole Nuechterlein (F.Hoffmann-La Roche)
Mineralys Therapeutics	Series BJun 2022$120M	$240M
Co-investors: Olivier Litzka (Andera Partners), Derek DiRocco (RA Capital)
Aura Biosciences	Post Ipo EquityNov 2021 Series UnknownMar 2021$80M Series CDec 2017$30M Series BMar 2015$21M	$130M
Co-investors: Mark Chin (Arix Bioscience)
Lava Therapeutics	Series CSep 2020$83M	$100M
Co-investors: Guido Magni (Versant Ventures), Nanna Luneborg (Forbion), Laia Crespo (Sanofi Ventures)
Ona Therapeutics	Series AJun 2020$34M	$46M
Co-investors: Jose Mesa (Alta Life Sciences)
AM Pharma	Series UnknownMar 2020$25M Series FJul 2019$130M Series ESep 2014$16M Series DSep 2011$40M	$210M
Co-investors: Geert-Jan Mulder (Forbion), Laia Crespo (Sanofi Ventures), Rémi Droller (Kurma Partners), Martijn Kleijwegt (EQT Life Sciences), Felice Verduyn - van Weegen (EQT Life Sciences), Raphael Wisniewski (Andera Partners)
Medlumics	Series BMar 2017$37M Series ADec 2011$5M	$64M
Co-investors: Olivier Litzka (Andera Partners)